AccessPak to treat HIV-related PEP expanded with Kaletra

Common Brands Actos
Drug Class
Controlled Substance Classification
Not a controlled medication
Generic Status
Lower-cost generic available
Prescription only
Kaci Durbin, MD
Kaci Durbin, MD
Read More
Medically reviewed by Kaci Durbin, MD last update on 20/12/2023


AccessPak, in conjunction with Kaletra, constitutes a vital component in the treatment paradigm for HIV-related Post-Exposure Prophylaxis (PEP). This combination serves as a robust emergency intervention, strategically designed to thwart the establishment of a permanent HIV infection subsequent to potential exposure. 

As a critical element in healthcare, it is particularly deployed in diverse scenarios, ranging from instances of unprotected sexual encounters to occupational exposures and sexual assault cases.

The effectiveness of AccessPak with Kaletra lies in its ability to leverage a combination of potent antiretroviral drugs, prominently featuring lopinavir and ritonavir, both belonging to the protease inhibitor class. 

By impeding the replication of the HIV virus, these medications act as formidable barriers, arresting its spread and preventing the virus from establishing a stronghold within the host’s body.



Prescription only

Pregnancy & Lactation